Edwards Lifesciences (NYSE:EW) Stock Rating Lowered by StockNews.com

Edwards Lifesciences (NYSE:EW – Get Rating) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Saturday.

Other research analysts have also issued research reports about the stock. Citigroup decreased their price target on shares of Edwards Lifesciences from $99.00 to $92.00 and set a “buy” rating on the stock in a research note on Monday, December 12th. Raymond James dropped their price target on shares of Edwards Lifesciences from $85.00 to $83.00 and set an “outperform” rating for the company in a research note on Tuesday, December 13th. Canaccord Genuity Group decreased their price objective on shares of Edwards Lifesciences from $106.00 to $91.00 and set a “hold” rating for the company in a research report on Friday, October 14th. Wells Fargo & Company reduced their price target on shares of Edwards Lifesciences from $121.00 to $93.00 and set an “overweight” rating for the company in a report on Friday, October 28th. Finally, Canaccord Genuity Group reduced their price target on shares of Edwards Lifesciences from $78.00 to $73.00 and set a “hold” rating for the company in a report on Monday, December 12th. Eight investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus price target of $99.68.

Edwards Lifesciences Stock Performance

EW stock opened at $79.29 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.83 and a quick ratio of 3.00. The company has a 50 day moving average price of $75.39 and a 200 day moving average price of $85.51. Edwards Lifesciences has a fifty-two week low of $67.13 and a fifty-two week high of $131.10. The stock has a market capitalization of $49.02 billion, a PE ratio of 34.18, a price-to-earnings-growth ratio of 2.72 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW – Get Rating) last announced its quarterly earnings results on Thursday, October 27th. The medical research company reported $0.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.01). The firm had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.34 billion. Edwards Lifesciences had a net margin of 27.20% and a return on equity of 24.75%. Analysts forecast that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In related news, VP Daveen Chopra sold 4,000 shares of the stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $74.18, for a total transaction of $296,720.00. Following the sale, the vice president now directly owns 18,911 shares of the company’s stock, valued at approximately $1,402,817.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, VP Donald E. Bobo, Jr. sold 6,725 shares of the firm’s stock in a transaction dated Tuesday, November 8th. The shares were sold at an average price of $68.46, for a total transaction of $460,393.50. Following the sale, the vice president now owns 62,561 shares of the company’s stock, valued at approximately $4,282,926.06. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Daveen Chopra sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $74.18, for a total transaction of $296,720.00. Following the sale, the vice president now directly owns 18,911 shares in the company, valued at approximately $1,402,817.98. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 91,800 shares of company stock valued at $6,933,324. 1.29% of the stock is owned by insiders.

Institutional Trading of Edwards Lifesciences

A number of institutional investors have recently made changes to their positions in EW. Bogart Wealth LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $25,000. MV Capital Management Inc. lifted its stake in shares of Edwards Lifesciences by 74.1% in the 3rd quarter. MV Capital Management Inc. now owns 329 shares of the medical research company’s stock worth $27,000 after purchasing an additional 140 shares during the period. Crewe Advisors LLC bought a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $28,000. Trifecta Capital Advisors LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $28,000. Finally, SouthState Corp bought a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $34,000. Hedge funds and other institutional investors own 80.35% of the company’s stock.

About Edwards Lifesciences

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.